Jeffery Won
Bispecific antibody-based immune-cell engagers have emerged as a groundbreaking approach in cancer immunotherapy, offering a novel means to harness the body's immune system to selectively target and eliminate cancer cells. These engineered antibodies possess the ability to bind two different antigens simultaneously, facilitating interactions between immune effector cells and tumor cells to enhance antitumor activity. The development of bispecific antibodies (BsAbs) has led to a new class of immunotherapeutics that bridge T cells or Natural Killer (NK) cells with cancer cells, thereby promoting targeted immune responses and reducing off-target effects associated with traditional therapies. One of the primary mechanisms by which bispecific antibodies function is through T cell redirection. These agents are designed to engage CD3, a key component of the T cell receptor complex, on one arm, while the other arm binds to a Tumor-Associated Antigen (TAA) expressed on cancer cells.
PDFShare this article
Journal of Genetics and DNA Research received 3 citations as per Google Scholar report
